US venture Acucela looks east for $125m IPO
This article was originally published in Scrip
Executive Summary
Acucela, a US venture specializing in ophthalmic disorders, is planning to raise up to $125m in an initial public offering in Tokyo to support the development and commercialization of its pipeline.